Sensitive tumor detection, accurate quantification, and cancer subtype classification using low-pass whole methylome sequencing of plasma DNA
Paoli, M.; Galardi, F.; Nardone, A.; Biagioni, C.; Romagnoli, D.; Di Donato, S.; Franceschini, G. M.; Livraghi, L.; Pestrin, M.; Sanna, G.; Risi, E.; Migliaccio, I.; Moretti, E.; Malorni, L.; Biganzoli, L.; Demichelis, F.; Benelli, M.
Show abstract
The analysis of circulating tumor DNA (ctDNA) is increasingly used for monitoring disease in patients with metastatic cancer. Here, we introduce a robust and reproducible strategy combining low-pass whole methylome sequencing of plasma DNA with METER, a novel computational tool. Engaging prediction models trained on independent available datasets, METER enables the detection and quantification of tumor content (TC) and performs molecular cancer subtyping. Applied to plasma methylomes from early metastatic breast cancer patients, our method demonstrated reliable quantification, sensitive tumor detection below 3% of TC, and the ability to perform accurate Estrogen Receptor (ER) subtyping. METER provided clinically relevant predictions, underscored by associations with relevant prognostic factors, robust correlation with matched circulating tumor cells, and highly correlated with patients outcomes in challenging scenarios as TC<3%. Our strategy provides comprehensive and sensitive analysis of plasma samples, serving as a valuable yet cost-effective precision oncology tool.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Multi-scale characterisation of homologous recombination deficiency in breast cancer 95%
- Novel temporal and spatial patterns of metastatic colonization from rapid-autopsy tumor biopsies 94%
- Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival 94%
Similar papers in this journal
- Cell-free multi-omics analysis reveals tumor status-informative signatures in gastrointestinal cancer patients' plasma 95%
- Deep Learning identifies new morphological patterns of Homologous Recombination Deficiency in luminal breast cancers from whole slide images. 95%
- Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes 94%
Similar papers in this journal
- Aberrant transcript usage induces homologous recombination deficiency and predicts therapeutic responses 94%
- Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma 94%
- Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response 94%
Similar papers in this journal
- Non-invasive multi-cancer detection using DNA hypomethylation of LINE-1 retrotransposons 96%
- Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer 96%
- cfTrack : Exome-wide mutation analysis of cell-free DNA to simultaneously monitor the full spectrum of cancer treatment outcomes: MRD, recurrence, and evolution 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.